Dry eye disease has a branding problem. The name suggests a minor inconvenience — a bit of gritty discomfort, easily fixed with a drop or two of artificial tears. For many people who develop significant dry eye in their fifties and sixties, the reality is considerably more disruptive: chronic irritation that interrupts concentration, fluctuating vision that makes reading unreliable, sensitivity to wind and air conditioning that limits time outdoors, and a persistent low-grade misery that accumulates across a day.
It’s also far more common than most people realize. Dry eye disease affects an estimated 16 million Americans with diagnosed disease and tens of millions more with symptoms that never get a formal diagnosis. Prevalence rises steeply with age, and the mechanisms driving it multiply as the decades pass. Understanding what’s actually happening in an aging dry eye — not just the surface-level symptom — is the starting point for managing it effectively.
Contents
The Tear Film and Why It Matters
A healthy ocular surface depends on a stable, well-distributed tear film that coats the eye between blinks. That film has three main components: a mucin layer secreted by goblet cells in the conjunctiva that allows the tear film to spread evenly across the hydrophobic corneal surface; an aqueous layer produced by the lacrimal glands that provides the bulk of tear volume; and a lipid layer secreted by the meibomian glands along the lid margins that retards evaporation and stabilizes the film between blinks.
Dry eye disease occurs when this system fails — either because tear production is inadequate, because tear quality is poor, or most commonly, because the lipid layer is deficient and tears evaporate too quickly. The distinction between aqueous-deficient dry eye (not enough tears being made) and evaporative dry eye (tears evaporating too fast due to meibomian gland dysfunction) matters practically because they respond differently to treatment. The majority of dry eye cases — roughly 85 percent in clinic populations — have a significant evaporative component driven by meibomian gland dysfunction.
Why Dry Eye Gets Worse With Age
Several age-related biological changes drive the increase in dry eye prevalence through the fifties, sixties, and beyond.
Lacrimal gland function declines gradually with age. The secretory acinar cells that produce aqueous tears become fewer and less active, and inflammatory changes in the gland reduce its responsiveness. The result is measurably lower basal tear production in older adults compared to younger ones. This decline is present in both sexes but is accelerated in women around and after menopause.
Meibomian gland dysfunction becomes more prevalent and more severe with age. The meibomian glands — the roughly 25 to 40 small glands in each eyelid that secrete the lipid layer — undergo age-related atrophy and fibrosis. Their secretions, which should be clear or slightly opalescent and free-flowing, become thickened and waxy with gland dropout and duct obstruction. The resulting lipid layer is thinner, less stable, and less protective against evaporation. Meibomian gland imaging (meibography) in older adults typically shows significant structural loss of functioning gland tissue.
Hormonal changes are a major driver, particularly for women. Androgens support both lacrimal gland and meibomian gland function; the androgen decline of menopause directly impairs tear production and lipid quality. This is why dry eye incidence and severity spike in the years around and after menopause, and why postmenopausal women have significantly higher dry eye rates than age-matched men. Oral estrogen supplementation without progesterone has been associated with worsening dry eye — a counterintuitive finding that has been replicated across several studies and is worth knowing if you’re considering or already using hormone therapy.
Blink rate and blink completeness also change with age. Partial blinks — where the lids don’t fully meet — become more common, leaving the lower third of the cornea less regularly wetted. This is compounded by the increased screen time of modern life: blink rate drops from a resting rate of roughly 15 blinks per minute to as few as 3 to 5 per minute during concentrated screen use, dramatically increasing tear evaporation.
The Inflammation Loop
One reason dry eye is so persistent in older adults is that chronic dry eye creates a self-reinforcing inflammatory cycle. Tear hyperosmolarity — the increased salt concentration that results from reduced tear volume or excessive evaporation — triggers inflammatory cytokine release at the ocular surface. This inflammation damages goblet cells and conjunctival epithelium, further impairing mucin production and tear film stability. The degraded tear film drives more hyperosmolarity. The cycle continues regardless of external triggers.
Breaking this cycle is the rationale for prescription anti-inflammatory treatments — cyclosporine ophthalmic emulsion and lifitegrast drops — which target the immune-mediated component of the disease rather than just lubricating the surface. These treatments can interrupt the inflammation loop in ways that over-the-counter artificial tears cannot. They’re often more appropriate for moderate to severe dry eye than repeated artificial tear instillation.
What Actually Helps
Dry eye management is appropriately stratified by severity. Mild symptoms might respond to a combination of environmental modifications and over-the-counter lubricants. More significant disease typically requires a more systematic approach.
Lid hygiene and warm compresses address the meibomian gland dysfunction component by softening inspissated meibum and improving gland expressibility. Daily warm compress application — at least ten minutes, with enough heat to penetrate the lid — is one of the more consistently useful self-management tools for evaporative dry eye. Lid scrubs and commercial lid hygiene products remove bacterial biofilm that contributes to lid inflammation and gland dysfunction.
Artificial tears in preservative-free formulations are appropriate for symptom relief, but formulation matters. Lipid-containing artificial tears (those containing phospholipids or oil-in-water emulsions) address the evaporative component more directly than aqueous-only formulations. Hyaluronic acid-based drops provide longer-lasting lubrication than simple saline-based formulations. If you’re instilling artificial tears more than four times daily, preservative-free unit-dose vials are strongly preferable, as the benzalkonium chloride preservative in multi-dose bottles is itself toxic to the ocular surface with frequent use.
Omega-3 fatty acids have a reasonable evidence base for dry eye, primarily for their effects on meibomian gland secretion quality and systemic anti-inflammatory effects. The most rigorous trial — the DREAM study — found no significant benefit over placebo for re-esterified omega-3s at the doses tested, which generated significant controversy. The broader literature, including multiple smaller trials and meta-analyses, is more supportive. Most dry eye specialists still recommend omega-3 supplementation as a component of management, particularly for meibomian gland dysfunction, while acknowledging the DREAM trial’s null finding.
Environmental modifications are underutilized but genuinely effective: humidifying indoor air (home humidifiers during winter and air conditioning seasons, where ambient humidity can drop below 20%), avoiding direct airflow from fans, vents, and car heating toward the face, and taking breaks from screen use using the 20-20-20 principle. The article on the 20-20-20 rule covers screen break strategies that also benefit dry eye significantly.
Punctal plugs — small silicone inserts placed in the drainage openings of the eyelids — conserve tear volume by reducing drainage and can provide significant symptom relief for aqueous-deficient dry eye. They’re a straightforward in-office procedure and reversible if needed. They’re less useful when the primary problem is evaporative rather than aqueous-deficient.
Note: Dry eye symptoms can overlap with those of other ocular surface conditions, including blepharitis, allergic conjunctivitis, and conjunctivochalasis. Persistent or severe symptoms, sudden changes in dry eye severity, or vision fluctuation beyond typical dry eye patterns warrant evaluation by an eye care professional for accurate diagnosis and appropriate management.
The Relationship With Overall Eye Health
Dry eye in older adults doesn’t exist in isolation. It interacts meaningfully with other age-related eye conditions. The ocular surface inflammation associated with chronic dry eye can affect the accuracy of intraocular pressure measurements used to screen for glaucoma, potentially masking elevated pressure or producing artifactually abnormal readings. Contact lens wear becomes more difficult to sustain with increasing dry eye severity. Cataract surgery outcomes are worse in patients with uncontrolled preoperative dry eye, which is why many surgeons now routinely screen and treat dry eye before scheduling surgery.
Getting dry eye adequately managed before other eye health procedures — not just tolerating it as a background annoyance — is a practical step that affects the quality of care you receive across the board. For a broader picture of what proactive eye health maintenance looks like in midlife, the article on protecting your eyes in your 40s covers the full strategic picture. The Performance Lab Vision review discusses the omega-3 and carotenoid evidence relevant to sustained ocular surface health.
